Symbyax is a combination medication containing the active ingredients found in Prozac (an SSRI antidepressant) and Zyprexa (an atypical antipsychotic). Both of these medications have been linked to a number of serious side effects, including suicidality, diabetes and birth defects.
Symbyax is manufactured by Eli Lilly & Co., which also markets Prozac and Zyprexa. The drug maker brought Symbyax to market in 2003, when the U.S. Food & Drug Administration (FDA) initially approved the medication to treat depressive episodes associated with bipolar disorder. In 2009, the approved indications for Symbyax were expanded to include the treatment of depression in adults who have already unsuccessfully tried two other medications.
Symbyax has been placed in Pregnancy Category C by the FDA, which indicates that risk to a developing fetus can not be ruled out.
In 2006, the FDA alerted the public to a possible association between SSRI antidepressants like Prozac, one of the ingredients in Symbyax, and persistent pulmonary hypertension of the newborn (PPHN). However, a later FDA alert indicated that studies published since 2006 have produced conflicting findings regarding a link between SSRIs and PPHN.
A number of studies have also suggested that the use of SSRIs in pregnancy may increase the risk for certain birth defects, including septal heart defects, an abdominal wall birth defect called Omphalocele, and a skull defect called Craniosynostosis. A recent study also found that children exposed to SSRIs during the last two trimesters of pregnancy were 117% more likely to be diagnosed with autism spectrum disorder.
Other Symbyax side effects may include:
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.